Lantern Pharma Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Lantern Pharma Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.18M) | Nov 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($4.33M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($4.33M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($4.54M) | May 15, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($4.54M) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($4.54M) | Nov 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($4.51M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.96M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($4.96M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.44M) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($5.44M) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($5.44M) | Aug 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($3.16M) | Nov 7, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($4.75M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($4.75M) | Aug 8, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($3.87M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($3.87M) | May 9, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($3.87M) | Nov 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($2.26M) | Nov 8, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($4.49M) | Aug 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.35M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($4.65M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($4.77M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.18M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($5.41M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.73M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($3.52M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($5.19M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.29M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($2.15M) | Nov 8, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($4.39M) | Aug 9, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($4.07M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($4.15M) | Nov 7, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($2.48M) | Aug 8, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($1.70M) | Nov 1, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($833.4K) | Jul 29, 2021 |